A Phase 3 interventional study of Combination of antibiotics and Emergency cerclage in Previable Labour With Intact Membranes, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, 2 of them phase 3. Premature Birth · Assistance Publique - Hôpitaux de Paris.
Among the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris, this one is the 9th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 3, and was the 24th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →6 of the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 6 yrs–78 mo
Assistance Publique - Hôpitaux de Paris · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 0 days–28 mo
By country, each count listing its studies:
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 133 across the 20 interventional studies, 253 across the 6 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Premature Birth by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03976063Phase 3Assistance Publique - Hôpitaux de ParisTocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation | 2026-11 |
| NCT05586334Assistance Publique - Hôpitaux de ParisDevelopment and Clinical Evaluation of an Innovative Medical Device to Predict Preterm Birth (PrediMAP) | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Premature Birth by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether a combination of antibiotics (cephalosporin 3rd generation, clarithromycin, metronidazole) are effective to prolong pregnancies complicated with previable threatened labour with intact membranes.
Observational data suggest that subclinical infectious conditions can lead to spontaneous preterm labor. 10% of births are premature, but the morbidity/mortality of premature babies is concentrated mainly among newborns born before 30 weeks of gestation or weighing less than 1500 g. The relationship to infection/inflammation and premature birth is not constant throughout pregnancy, but this infectious risk increases the earlier the gestational age of spontaneous labor is (before 30 weeks). The pathogens that have the strongest associations with premature birth are Gardnerella vaginalis, Ureaplasma urealyticum and Mycoplasma hominis, but also Streptococcus B, Escherichia coli, Klebsiella spp, or Haemophilus influenzae.
Antibiotic treatment to treat an intra-amniotic infection is considered ineffective. Indeed, the last randomized trial (Oracle 2, 2001), which studied several antibiotic regimens for threatened premature delivery with intact membranes, did not find a significant reduction in neonatal morbidity/mortality after administration of co-beta-lactam, erythromycin or the combination of both. In addition, this large trial dominates the results of the latest Cochrane meta-analysis which evaluated preventive antibiotic therapy to stop premature labor with intact membranes.
Recently, it has been showed that a new combination of antibiotics (ceftriaxone, clarithromycin and metronidazole) reduced the risk of infection and intra-amniotic inflammation in preterm labor with intact membranes. This retrospective study deserves to be confirmed by a randomized study
The investigator's goal is to study whether a new combination of antibiotics in a very limited population of pregnancies complicated by the threat of late miscarriage would make it possible to prolong pregnancies in order to improve neonatal outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination of antibiotics (3rd generation of cephalosporin, clarithromycin, metronidazole) \+ routine care (emergency cerclage, vaginal progesterone)
Drug: Combination of antibiotics · Device: Emergency cerclage · Drug: Vaginal progesterone
Routine care (emergency cerclage, vaginal progesterone)
Device: Emergency cerclage · Drug: Vaginal progesterone
Ceftriaxone : 1g/day parenteral clarithromycin 500 mg\*2/day orally metronidazole 500mg\*3/ day orally
Also known as: Ceftriaxone; clarithromycin, metronidazole
Emergency cerclage
Vaginal progesterone
A perinatal composite outcome
* Late miscarriage * Perinatal mortality * Bronchodysplasia, * Sepsis proven by blood culture, * Intraventricular hemorrhage ≥3, * Periventricular leukomalacia ≥2, * Ulcero-necrotizing enterocolitis at stage ≥2 according to the Bell classification.
Time frame: Up to 24 weeks
Gestationnal age at delivery
* Gestationnal age at delivery ≥ 24 weeks of gestation (wg) 0/7, 28 wg0/7, 32 wg0/7, 34 wg0/7 et 37 wg0/7 * Latency period between randomisation and delivery (≥2 days, ≥7 days, ≥14 days et ≥28 days)
Time frame: 6 months
Maternal Morbidty
Chorioamniotitis, postpartum endometritis , sepsis proven par positive hemocultures
Time frame: 6 months
Bacteriological
Acquisition of multi-resistant germs during childbirth
Time frame: 6 months
Start is estimated for Sep 2026; primary completion for May 2030, 44 months later.
Of 35 non-industry phase 3 interventional studies under Premature Birth, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 89. This study's planned 44 months is below that.
Counting every sponsor, half of 40 studies reached it within 51 months; a quarter within 28 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →